

PUBLICATIONS Galon J (* corresponding author)

Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, Waldner M, Berger A, Fridman WH, Rafii A, Valge-Archer V, Pagès F, Speicher MR, **Galon J.***

Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients.

Science Transl. Med. 2014 Mar 19;6(228)

Galon J*, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F. Towards the introduction of the Immunoscore in the classification of malignant tumors.

J Pathol. 2014 Jan;232(2):199-209.

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell HK, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, **Galon J***

Spatio-temporal dynamics of intratumoral cells reveal the immune landscape in human cancer

Immunity. 2013 Oct 17;39(4):782-95. (IF: 20.72)

Galon J*, Angell HK, Bedognetti D, and Marincola F

The continuum of cancer immunosurveillance: prognostic, predictive and mechanistic signatures

Immunity. 2013 July 39(1), 11-26 (IF: 20.72)

Aranda F, Vacchelli E, Eggermont A, **Galon J**, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.

Oncoimmunology. 2014 Jan 1;3(1):e27297.

Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferariu D, Danciu M, Bruneval P, Scripcariu V, Chevallier JM, Zinzindohoué F, Berger A, **Galon J**, Pagès F.

Prognostic and predictive values of the immunoscore in patients with rectal cancer.

Clin Cancer Res. 2014 Apr 1;20(7):1891-9.

Vacchelli E, Aranda F, Eggermont A, **Galon J**, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

Oncoimmunology. 2014 Jan 1;3(1):e27048.

Aranda F, Vacchelli E, Eggermont A, **Galon J**, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Peptide vaccines in cancer therapy.

Oncoimmunology. 2013 Dec 1;2(12):e26621.

Semeraro M, Vacchelli E, Eggermont A, **Galon J**, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Lenalidomide-based immunochemotherapy.

Oncoimmunology. 2013 Nov 1;2(11):e26494.

Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, **Galon J**, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Anticancer radioimmunotherapy.

Oncoimmunology. 2013 Sep 1;2(9):e25595.

Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, **Galon J**, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Dendritic cell-based interventions for cancer therapy.

Oncoimmunology. 2013 Oct 1;2(10):e25771.

Vacchelli E, Eggermont A, Sautès-Fridman C, **Galon J**, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Toll-like receptor agonists for cancer therapy.

Oncoimmunology. 2013 Aug 1;2(8):e25238.

Vacchelli E, Eggermont A, Fridman WH, **Galon J**, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Immunostimulatory cytokines.

Oncoimmunology. 2013 Jul 1;2(7):e24850.

Vacchelli E, Eggermont A, Sautès-Fridman C, **Galon J**, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Oncolytic viruses for cancer therapy.

Oncoimmunology. 2013 Jun 1;2(6):e24612.

Vacchelli E, Eggermont A, Fridman WH, **Galon J**, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Oncoimmunology. 2013 May 1;2(5):e24238.

Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, **Galon J**, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: DNA vaccines for cancer therapy.

Oncoimmunology. 2013 Apr 1;2(4):e23803.

Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, **Galon J**, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenart P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"

J Transl Med. 2013 Jun 3;11(1):137.

Vacchelli E, Senovilla L, Eggermont A, Fridman WH, **Galon J**, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Chemotherapy with immunogenic cell death inducers.

Oncoimmunology. 2013 Mar 1;2(3):e23510.

Angell H, **Galon J***

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer.

Curr Opin Immunol. 2013 Apr;25(2):261-7.

Vacchelli E, Eggermont A, **Galon J**, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Monoclonal antibodies in cancer therapy.

Oncoimmunology. 2013 Jan 1;2(1):e22789.

Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, **Galon J**, Fox BA.

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.

J Transl Med. 2013 Mar 3;11:54.

Bindea G, **Galon J**, Mlecnik B.

CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data.

Bioinformatics. 2013 Mar 1;29(5):661-3.

Vacchelli E, Martins I, Eggermont A, Fridman WH, **Galon J**, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Peptide vaccines in cancer therapy.

Oncoimmunology. 2012 Dec 1;1(9):1557-1576.

Senovilla L, Vacchelli E, **Galon J**, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Oncoimmunology. 2012 Nov 1;1(8):1323-1343.

Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, **Galon J**, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Trial watch: Dendritic cell-based interventions for cancer therapy.

Oncoimmunology. 2012 Oct 1;1(7):1111-1134.

Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, **Galon J**, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Oncoimmunology. 2012 Sep 1;1(6):894-907.

Fridman WH, Dieu-Nosjean MC, Pagès F, Cremer I, Damotte D, Sautès-Fridman C, **Galon J**.

The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact.

Cancer Microenviron. 2012 Oct 30. [Epub ahead of print]

Galon J*, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Hartmann A, Aszlaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

Cancer classification using the Immunoscore: a worldwide task force.

J Transl Med. 2012 Oct 3;10(1):205.

Charoentong P, Angelova M, Efremova M, Gallasch R, Hackl H, **Galon J**, Trajanoski Z.

Bioinformatics for cancer immunology and immunotherapy.

Cancer Immunol Immunother. 2012 Nov;61(11):1885-903.

Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, **Galon J**, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.
Oncoimmunology. 2012 Aug 1;1(5):699-716.

Vacchelli E, Galluzzi L, Eggermont A, **Galon J**, Tartour E, Zitvogel L, Kroemer G.
Trial Watch: Immunostimulatory cytokines.
Oncoimmunology. 2012 Jul 1;1(4):493-506.

Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, **Galon J**, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.
Trial Watch: Adoptive cell transfer immunotherapy.
Oncoimmunology. 2012 May 1;1(3):306-315.

Vacchelli E, Galluzzi L, Fridman WH, **Galon J**, Sautès-Fridman C, Tartour E, Kroemer G.
Trial watch: Chemotherapy with immunogenic cell death inducers.
Oncoimmunology. 2012 Mar 1;1(2):179-188.

Galluzzi L, Vacchelli E, Fridman WH, **Galon J**, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G.
Trial Watch: Monoclonal antibodies in cancer therapy.
Oncoimmunology. 2012 Jan 1;1(1):28-37.

Emens LA, Silverstein SC, Khleif S, Marincola FM, **Galon J***.
Toward integrative cancer immunotherapy: targeting the tumor microenvironment.
J Transl Med. 2012 Apr 10;10:70.

Fridman WH, Pagès F, Sautès-Fridman C, **Galon J***.
The immune contexture in human tumours: impact on clinical outcome.
Nat Rev Cancer. 2012 Mar 15;12(4):298-306. doi: 10.1038/nrc3245.

Galon J*, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA.
The immune score as a new possible approach for the classification of cancer.
J Transl Med. 2012 Jan 3;10:1.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, **Galon J**, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.
Defining the critical hurdles in cancer immunotherapy.
J Transl Med. 2011 Dec 14;9(1):214.

Fridman WH, **Galon J**, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G.
Prognostic and predictive impact of intra- and peritumoral immune infiltrates.
Cancer Res. 2011 Sep 1;71(17):5601-5. Epub 2011 Aug 16. Review.

Ogino S, **Galon J**, Fuchs CS, Dranoff G.
Cancer immunology--analysis of host and tumor factors for personalized medicine.
Nat Rev Clin Oncol. 2011 Aug 9;8(12):711-9. doi: 10.1038/nrclinonc.2011.122. Review.

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients.

Bindea G, Mlecnik B, Fridman WH, **Galon J***.
Semin Immunopathol. 2011 Jul;33(4):335-40.

Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.

Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, **Galon J***.
Cancer Res. 2011 Feb 15;71(4):1263-71

hSMG-1 is a granzyme B-associated stress-responsive protein kinase.

Meslin F, Hamaï A, Mlecnik B, Rosselli F, Richon C, Jalil A, Wemhoff G, Thiery J, **Galon J**, Chouaib S.
J Mol Med 2011 Apr;89(4):411-21.

Tumor immunosurveillance in human cancers.

Mlecnik B, Bindea G, Pagès F, **Galon J***.
Cancer Metastasis Rev. 2011 Mar;30(1):5-12.

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, **Galon J***.
J Clin Oncol. 2011 Feb 20;29(6):610-8.

Immunosurveillance in human non-viral cancers.

Fridman WH, Mlecnik B, Bindea G, Pagès F, **Galon J***.
Curr Opin Immunol. 2011 Apr;23(2):272-8.

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010".

Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, **Galon J**, Ribas A, Yang J, Stronck DF, Mozzillo N, Marincola FM.
J Transl Med. 2011 Mar 26;9:32.

Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy.

Hackl H, Stocker G, Charoentong P, Mlecnik B, Bindea G, **Galon J***, Trajanoski Z.
Pharmacol Ther. 2010 Dec;128(3):488-98.

Memory T-cell responses and survival in human cancer: remember to stay alive.

Camus M, **Galon J***
Adv Exp Med Biol. 2010; 684:166-77.

Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control.

Fridman WH, **Galon J**, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, Pagès F, Tartour E, Sautès-Fridman C.

Curr Top Microbiol Immunol. 2010 May 29.

Natural immunity to cancer in humans.

Bindea G, Mlecnik B, Fridman WH, Pagès F, **Galon J***

Curr Opin Immunol. 2010 Apr;22(2):215-22

Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction

Mlecnik B, Sanchez-Cabo F, Charoentong P, Bindea G, Pages F, Berger A, **Galon J***, Trajanoski Z

BMC Genomics 2010 Feb 10;11 Suppl 1:S7.

Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Pagès F, **Galon J**, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH.

Oncogene. 2010 Feb 25;29(8):1093-102.

Biomolecular network reconstruction identifies T cell homing factors associated with survival in colorectal cancer

Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, Pages F, Trajanoski Z, **Galon J***

Gastroenterology 2010 Apr;138(4):1429-40.

The *in situ* cytotoxic and memory T cells predict outcome in early-stage colorectal cancer patients

Pages F, Kirilovsky A, Mlecnik B, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman W-H, **Galon J***

J Clin Oncol 2009. 27(35):5944-51.

ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks

Bindea G*, Mlecnik B*, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman W-H, Pages F, Trajanoski Z, **Galon J***

Bioinformatics 2009. 25(8):1091-1093

Coordination of intratumoral immune reaction and human colorectal cancer recurrence

Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A, Costes A, Bindea G, Charoentong P, Bruneval P, Trajanoski Z, Fridman W-H, **Galon J***

Cancer Res 2009. 69(6):2685-93

Pagès F, **Galon J**, Fridman WH

The essential role of the *in situ* immune reaction in human colorectal cancer

J Leuk Biol. 84(4):981-7, 2008

Potential immunologic consequences of lymph node dissection in colorectal cancer

Pagès F, Berger A, Zinzindohoué F, Kirilovsky A, **Galon J**, Fridman WH.

J Chir. 2008 Dec;145 Spec no. 4:12S6-12S12.

The adaptive immunologic microenvironment in colorectal cancer: a novel perspective

Galon J*, Fridman WH, Pages F

Cancer Res 2007. 67:1883-6

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Galon J*, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc P-H, Trajanoski Z, Fridman W-H, Pages F
Science 2006.313:1960-4

Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure
Abouzahr S, Bismuth G, Gaudin C, Carroll O, Van Endert P, Jalil A, Dausset J, Vergnon I, Richon C, Kauffmann A, **Galon J**, Raposo G, Mami-Chouaib F, Chouaib S
Proc Natl Acad Sci U S A 2006.103:1428-33

Effector memory T cells, early metastasis, and survival in colorectal cancer.
Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molitor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, **Galon J***
N Engl J Med. 2005 Dec 22;353(25):2654-66.

Pages F, **Galon J**, Karaschuk G, Dudziak D, Camus M, Camilleri-Broet S, Lagorce Pages C, Lazar V, Lebel Binay S, Laux G, Fridman WH, Henglein B. Epstein-barr virus nuclear antigen 2 induces expression of interleukin 18 receptor in B-cells.
Blood. 105(4):1632-9, 2005

Franchimont D, Kino T, **Galon J**, Meduri GU, Chrousos G.
Glucocorticoids and Inflammation Revisited: The State of the Art. NIH Clinical Staff Conference.
Neuroimmunomodulation. 10(5):247-60, 2003.

Franchimont D*, **Galon J***, Vacchio MS, Fan S, Visconti R, Frucht DM, Geenen V, Chrousos GP, Jonathan D. Ashwell JD, and O'Shea JJ. Positive effects of glucocorticoids on T cell function by upregulation of Interleukin-7 Receptor a.
J. Immunol.;168(5):2212-8., 2002. * Equal contribution

Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O'Shea JJ, Chrousos GP, and Bornstein SR
Gene Profiling Reveals Unknown Enhancing and Suppressive Actions of Glucocorticoids on Immune Cells
FASEB J. 16(1):61-71, 2002.

Tang P, Cheng TP, Agnello D, Wu CY, Hissong BD, Watford WT, Ahn HJ, **Galon J**, Moss J, Vaughan M, O'Shea JJ, Gadina M. Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity.
Proc Natl Acad Sci U S A. 99(5):2625-2629, 2002 .

Cassard L, Cohen-Solal JF, Galinha A, Sastre-Garau X, Mathiot C, **Galon J**, Dorval T, Bernheim A, Fridman WH, Sautes-Fridman C. Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells.
J Clin Invest. 2002 Nov 15;110(10):1549-1557.

Aksentjevich I, **Galon J**, Soares M, Mansfield E, Hull K, Oh HH, Goldbach-Mansky R, Dean J, Athreya B, Reginato AJ, Henrickson M, Pons-Estel B, O'Shea JJ, and Kastner DL.
The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.
Am J Hum Genet. 69(2):301-14, 2001.

Bouhlal H, **Galon J**, Kazatchkine MD, Fridman WH, Sautes-Fridman C, Haeffner Cavillon N. Soluble CD16 Inhibits CR3 (CD11b/CD18)-Mediated Infection of Monocytes/Macrophages by Opsonized Primary R5 HIV-1.

J Immunol 166(5):3377-3383, 2001

Maurer M, Trajanoski Z, Frey G, Hiroi N, **Galon J**, Chrousos GP, Scherbaum WA, Bornstein SR. Differential gene expression profile of glucocorticoids, testosterone, and dehydroepiandrosterone on human immune cells

Horm Metab Res. 33(12):691-5, 2001

Franchimont D *, **Galon J** *, Gadina M, Visconti R, Zhou YJ, Aringer M, Frucht DM, Chrousos GP and O'Shea JJ. Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits Interleukin-12 (IL-12) -Induced Stat4 Phosphorylation in T Lymphocytes.

J. Immunol. 164(4):1768-74, 2000. * Equal contribution

Galon J, Aksentijevich I, McDermott MF, O'Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes.

Curr Opin Immunol. 12(4):479-86, 2000. (review)

Centola M *, Wood G *, Frucht DM, **Galon J**, Aringer M, Farrell C, Kingma DW, Horwitz ME, Mansfield E, Holland SM, O'Shea JJ, Rosenberg HF, Malech HL, Kastner DL. The Gene for Familial Mediterranean Fever, *MEFV*, is Expressed in Early Leukocyte Development and is Regulated in Response to Inflammatory Mediators

Blood, 95(10):3223-31, 2000.

Zhou YJ, Magnuson KS, Cheng TP, Gadina M, Frucht DM, **Galon J**, Candotti F, Geahlen RL, Changelian PS, O'Shea JJ. Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation.

Mol Cell Biol. 20(12):4371-80, 2000.

Frucht DM, Aringer M, **Galon J**, Danning C, Brown M, Fan S, Centola M, Wu CY, Yamada N, El Gabalawy H, O'Shea JJ. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation.

J Immunol. 164(9):4659-64, 2000.

Franchimont D, Bouma G, **Galon J**, Wolkersdorfer GW, Haidan A, Chrousos GP, Bornstein SR. Adrenal cortical activation in murine colitis.

Gastroenterology. 119(6):1560-8, 2000.

Ashwell JD, Vacchio MS, **Galon J**. Do glucocorticoids participate in thymocyte development?

Immunol Today. 21(12):644-6, 2000.

McDermott MF *, Aksentijevich I *, **Galon J** *, McDermott EM, Ogunkolade BW, Centola M, Mansfield E, Gadina M, Karenko L, Pettersson T, McCarthy J, Frucht DM, Aringer M, Torosyan Y, Teppo AM, Wilson M, Karaarslan HM, Wan Y, Todd I, Wood G, Schlimgen R, Kumarajeewa TR, SM, Vella JP, Amos CI, Mulley J, Quane KA, Molloy MG, Ranki A, Powell RJ, Hitman GA, O'Shea JJ, and Kastner DL. Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor (TNFR1) Define a Family of Dominantly Inherited Autoinflammatory Syndromes.

Cell, 97 (1), 133-144, 1999. * Equal contribution

Galon J, Sudarshan C, Ito S, Finbloom D, and O'Shea JJ. IL-12 induces interferon regulating factor-1 (IRF-1) gene expression in human NK and T cells

J. Immunol. 162, 7256-7262, 1999.

Sudarshan C, **Galon J**, Zhou YJ and O'Shea JJ. TGF-beta Does Not Inhibit IL-12- and IL-2- Induced Activation of Janus Kinases and STATs.
J. Immunol. 162(5), 2974-2981, 1999.

Leonetti M, **Galon J**, Thai R, Sautes-Fridman C, Moine G, Menez A. Presentation of Antigen in Immune Complexes Is Boosted by Soluble Bacterial Immunoglobulin Binding Proteins.
J. Exp. Med. 189 (8), 1217-1228, 1999.

Moldovan I, **Galon J**, Maridonneau-Parini I, Mathiot C, Fridman WH and Sautès-Fridman C. Regulation of production of soluble Fc gamma receptor type III in normal and pathological conditions.
Immunology Letters, 68(1):125-34, 1999.

Mathiot C, **Galon J**, Teillaud JL, Tartour E, Facon T, Bataille R, Fridman WH, and Sautes C. Role of soluble CD16 in multiple myeloma. Soluble CD16 in plasma cell dyscrasias.
Leukemia and Lymphoma, 32(5-6), 467-474, 1999.

Chen EH, Gadina M, **Galon J**, Chen M, and O'Shea JJ. Not just another meeting: the coming of age of Jaks and STATs.
Immunology Today. 19 (8):338-340, 1998.

Galon J, Moldovan I, Galinha A, Provost-Marloie MA, Kaudewitz H, Roman-Roman S, Fridman WH and Sautès C. Identification of the cleavage site involved in production of soluble form of Fc gamma receptor type (CD16).
Eur. J. Immunol. 28:2101-2107, 1998.

Haegel-Kronenberger H, Bohbot A, **Galon J**, De la Salle H and Hanau D. Cytokines and dendritic cells.
M S-Medecine Sciences 14 (4), 429-436, 1998.

Galon J, Paulet P, Galinha A, Lores P, Bonnerot C, Jami J, Fridman WH and Sautes C. Soluble Fc gamma receptors: interaction with ligands and biological consequences.
Int. Rev. Immunol. 16(1-2), 87-111, 1997.

Galon J, Robertson M, Galinha A, Mazières N, Spagnoli R, Fridman WH and Sautès C. Affinity and specificity of the interaction between Fc gamma receptor type III and human IgG subclasses. Role of Fc gamma receptor type III glycosylation.
Eur. J. Immunol. 27 (8), 928-1932, 1997.

Vely F, Gruel N, Montcuit J, Cochet O, Rouard H, Dare S, **Galon J**, Sautès C, Fridman WH and Teillaud JL. A new set of monoclonal antibodies against human FcγRII (CD32) and FcγRIII (CD16) : Characterization and use in various assays.
Hybridoma 16 (6), 519-528, 1997.

De la Salle H, **Galon J**, Bausinger H, Spehner D, Bohbot A, Cohen J, Cazenave JP, Fridman WH, Sautes C and Hanau D. Soluble CD16/Fc gamma RIII induces maturation of dendritic cells and production of several cytokines including IL-12.
Adv Exp Med Biol; 417:345-52, 1997.

Haegel-Kronenberger H, De la Salle H, Bohbot A, **Galon J**, Tartour E, Cazenave JP and Hanau D. Regulation of CD44 isoform expression and CD44-mediated signaling in human dendritic cells.
Adv Exp Med Biol; 417:83-90, 1997.

Galon J, Gauchat JF, Galinha A, Mazières N, Spagnoli R, Storkus W, Lötze M, Bonnefoy JY, Fridman WH and Sautès C. Soluble Fcγ receptor type III (FcγRIII, CD16) triggers cell activation through interaction with complement receptors.
J. Immunol. 157, 1184-1192, 1996.

Galon J, Bouchard C, Fridman WH and Sautès C. Ligands and biological activities of soluble Fcγ receptors.
Immunology Letters, 44, 175-181, 1995

Sandor M, **Galon J**, Takacs L, Tatsumi Y, Mueller AL, Sautès C and Lynch RG. An alternative Fcγ receptor ligand: potential role in T cell development.
Proc. Natl. Acad. Sci. USA 91, 12857-12861, 1994.

Teillaud C, **Galon J**, Zilber MT, Mazières N, Spagnoli R, Kurrle R, Fridman WH and Sautès C. Soluble CD16 binds peripheral blood mononuclear cells and inhibits pokeweed-mitogen-induced responses.
Blood, 85, (10), 3081-3090, 1993.

Fridman WH, Teillaud JL, Bouchard C, Teillaud C, Astier A, Tartour E, **Galon J**, Mathiot C and Sautès C. Soluble Fcγ receptors.
J. Leuk. Biol. 54, 504-512, 1993.